Kuboyama, Kazuya Tanga, Naomi Suzuki, Ryoko Fujikawa, Akihiro Noda, Masaharu Schematic representation of cell-based assays for oligodendrocyte differentiation activators. <p>Many small molecules with the ability to enhance OPC differentiation and remyelination <i>in vivo</i> have been reported to date: ARA-014418 (glycogen synthase kinase 3 (GSK3) β inhibitor) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref023" target="_blank">23</a>], 9-<i>cis</i>-retinoic acid (retinoid X receptor agonist) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref024" target="_blank">24</a>], rolipram (phosphodiesterase (PDE) 4 inhibitor) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref025" target="_blank">25</a>], benztropin (M1/M3 muscarinic receptor agonist) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref026" target="_blank">26</a>], clemastine (antihistamine and anticholinergic) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref027" target="_blank">27</a>], quetiapine (antipsychotic drug) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref028" target="_blank">28</a>], solifenacin (M3 inhibitor) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref029" target="_blank">29</a>], clobetasol (synthetic adrenocortical hormone), miconazole (antifungal agent) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref030" target="_blank">30</a>], tamoxifen (estrogen receptor modulator for ERα, ERβ, and GPR30) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref031" target="_blank">31</a>], U-50488 (kappa-opioid receptor agonist) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref032" target="_blank">32</a>], XAV939 (tankyrase inhibitor) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref033" target="_blank">33</a>], and VP3.15 (PDE7 and GSK3 dual inhibitor) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189164#pone.0189164.ref034" target="_blank">34</a>]. However, most of these do not have the potential to overcome the inhibitory activities of CSPGs. We used OL1 cells cultured on aggrecan-coated substrates as a model of CSPG deposition on demyelinated plaques, and screened compounds that overcome inhibitory activity against differentiation of oligodendrocyte precursor cells (OPCs) to oligodendrocytes (OLs).</p> oligodendrocyte differentiation Chondroitin sulfate proteoglycans;PRM;protein tyrosine phosphatase receptor type Z;CSPG;chondroitin sulfate proteoglycan-mediated inhibition;MS;mouse OPC-like OL 1 cells;oligodendrocyte precursor cells;oligodendrocyte differentiation;CNS;PTPRZ 2017-12-07
    https://plos.figshare.com/articles/figure/Schematic_representation_of_cell-based_assays_for_oligodendrocyte_differentiation_activators_/5680051
10.1371/journal.pone.0189164.g001